Effect of Honey Phonophoresis on Knee Cartilage Thickness
Influence of Honey Phonophoresis on Cartilage Thickness in Patients With Knee Osteoarthritis
1 other identifier
interventional
50
1 country
2
Brief Summary
Osteoarthritis (OA) is a progressive chronic disease with the loss of articular cartilage. It is now well recognized that the progression of the disease involves erosion of the cartilage, osteochondral inflammatory damage, and bone distortion. Many recent medical procedures provide treatment through improving symptoms through tissue regeneration and restoring homeostasis to local cells. Unlike bone, articular cartilage is rather recalcitrant to regenerate. Honey is a natural material contain 200 distinct chemical compounds in honey including a wide range of phenolic compounds that have antioxidant, bacteriostatic, antimicrobial, and anti-inflammatory properties. Honey was found to increase the printability and chondrogenic potential of a naturally derived bioink are the main formulations used as hydrogel for Articular Cartilage (AC) regeneration due to their similarity to chondral tissue in terms of morphological and mechanical properties. Design: Double blinded, Randomized control trial. Methods: 50 osteoarthritic patients will be evaluated to be allocated after they match the inclusion criteria then randomized to two groups, group A for Phonophoresis using Honey as coupling media with conventional physical therapy program, group B for ultrasound with regular gel as a coupling media with conventional physical therapy. Outcome measures: the primary outcome measure will be the thickness of the cartilage will be measured using diagnostic ultrasound, the secondary outcome measure will be knee pain measured by the visual analog scale (VAS) and Western Ontario and McMaster Universities OA Index (WOMAC) pain subscale, also functional mobility which will be measured using the stiffness and physical function subscales of the total WOMAC. All will be measured 1 day before starting the procedures and after 4 weeks of the intervention 3sessions/week.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable knee-osteoarthritis
Started Jan 2024
Shorter than P25 for not_applicable knee-osteoarthritis
2 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 30, 2023
CompletedFirst Posted
Study publicly available on registry
January 11, 2024
CompletedStudy Start
First participant enrolled
January 15, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 15, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
March 15, 2024
CompletedFebruary 21, 2024
February 1, 2024
1 month
December 30, 2023
February 19, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
cartilage thickness
knee joint cartilage thickness
4 weeks
Secondary Outcomes (2)
Pain severity
4 weeks
Functional mobility
4 weeks
Study Arms (2)
Honey Group
EXPERIMENTALwill receive phonophoresis with honey and conventional physical therapy treatment in the form of transcutaneous electrical nerve stimulation (TENS) current and exercise . The parameters of the application of phonophoresis will be the continuous modality, 1 MHz frequency, intensity of 1 or 1.5 W/cm2, and an application time of 10 minutes
Control Group
OTHERwill receive ultrasound therapy with gel media and the same conventional physical therapy treatment (control group)
Interventions
TENS, Strengthening, and stretching exercises
Eligibility Criteria
You may qualify if:
- bilateral mild-to-moderate medial tibiofemoral Osteoarthritis
You may not qualify if:
- rheumatologic conditions such as:
- rheumatoid arthritis,
- severe knee OA,
- thrombosis of the lower limbs,
- patients who had physiotherapy treatment of the knee in the previous 6 months,
- a history of injections in the knee joint during the last 6 months,
- balance disorders,
- neuropathy or sensory disorders,
- skin damage around the knee,
- previous surgery on the knee joint, or a previous fracture of the lower extremity with knee joint involvement.
- Patients will be also excluded if they have any contraindications or precautions for the use of ultrasound (e.g., infection, heart problems, pacemaker, metal implants, open epiphysis, pregnancy, thrombophlebitis, or impaired sensation)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (2)
Jazan University
Jizan, Gizan, 45142, Saudi Arabia
Jazan University
Jizan, Gizan, 45142, Saudi Arabia
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Abdelrahman Elsayegh, Associate professor
University of Jazan
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assistant professor
Study Record Dates
First Submitted
December 30, 2023
First Posted
January 11, 2024
Study Start
January 15, 2024
Primary Completion
February 15, 2024
Study Completion
March 15, 2024
Last Updated
February 21, 2024
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share